Seeking Alpha

Cowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from...

Cowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from "neutral," saying that the pharma play has high visibility and revenue predictability. Cowen also assumes an expanded EU label for Revlimid in 2015 despite last week's regulatory setback for the drug. Cowen's note comes after other firms cut their price targets on Celgene.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector